Pacific Edge Biotechnology Limited
Records under this name other than the patents Pacific Edge Biotechnology Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Pacific Edge Biotechnology Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,822,149 | Prognosis Prediction for Melanoma Cancer Formerly held Lapsed on the fee record Ended Sep 2, 2026 · High confidence | Lapsed on the fee record | Ended Sep 2, 2026 | High confidence |
| US 10,024,859 | Markers for Detection of Gastric Cancer Formerly held Lapsed on the fee record Ended Jul 17, 2026 · High confidence | Lapsed on the fee record | Ended Jul 17, 2026 | High confidence |
| US 11,180,815 | Methods for treating colorectal cancer using prognostic genetic markers Lapsed on the fee record Ended Nov 23, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 23, 2025 | USPTO record |
| US 9,809,860 | Test Kits and Methods for Their Use in Detecting Expression Ratios of Genetic Markers Formerly held Lapsed on the fee record Ended Nov 7, 2025 · Medium confidence | Lapsed on the fee record | Ended Nov 7, 2025 | Medium confidence |
| US 11,130,789 | Urine markers for detection of bladder cancer Formerly held Lapsed on the fee record Ended Sep 28, 2025 · High confidence | Lapsed on the fee record | Ended Sep 28, 2025 | High confidence |
| US 9,702,009 | Urine Gene Expression Ratios for Detection of Cancer Formerly held Lapsed on the fee record Ended Jul 11, 2025 · Medium confidence | Lapsed on the fee record | Ended Jul 11, 2025 | Medium confidence |
| US 9,534,258 | Devices and Methods for Prognosis Prediction for Melanoma Cancer Formerly held Lapsed on the fee record Ended Jan 3, 2025 · High confidence | Lapsed on the fee record | Ended Jan 3, 2025 | High confidence |
| US 10,689,707 | Treatment of recurrent gastric cancer identified using genetic biomarkers Formerly held Lapsed on the fee record Ended Jun 23, 2024 · USPTO record | Lapsed on the fee record | Ended Jun 23, 2024 | USPTO record |
| US 7,370,021 | Medical applications of adaptive learning systems using gene expression data Formerly held Term ended Term ended Mar 21, 2024 · USPTO record | Term ended | Term ended Mar 21, 2024 | USPTO record |
| US 10,422,005 | Methods for treating colorectal cancer using prognostic genetic markers Lapsed on the fee record Ended Sep 24, 2023 · USPTO record | Lapsed on the fee record | Ended Sep 24, 2023 | USPTO record |